Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

Malvern, Pennsylvania Tuesday, July 22, 2025, 17:00 Hrs [IST] ...

Naik questioned the purpose of these 19 years and what the matter was that had caused the case to drag on so long. He said that after bomb blasts took place in 2002 and 2008, all the accused were ...

Investing.com -- Replimune Group, Inc. (NASDAQ: REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...